Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

This study has been terminated.
(Poor accrual.)
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: August 2, 2005
Last updated: February 27, 2013
Last verified: February 2013
This phase II trial is studying how well trastuzumab works in treating patients with metastatic or recurrent salivary gland cancer. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them

Condition Intervention Phase
High-grade Salivary Gland Mucoepidermoid Carcinoma
Recurrent Salivary Gland Cancer
Salivary Gland Acinic Cell Tumor
Salivary Gland Adenocarcinoma
Salivary Gland Poorly Differentiated Carcinoma
Stage IVA Salivary Gland Cancer
Stage IVB Salivary Gland Cancer
Stage IVC Salivary Gland Cancer
Biological: trastuzumab
Other: laboratory biomarker analysis
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Response (confirmed and unconfirmed, complete and partial response) in patients treated with trastuzumab [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]
    A true response probability of 30% or greater would be of interest.

Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 1 year ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]

Enrollment: 35
Study Start Date: July 2005
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (trastuzumab)
Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Biological: trastuzumab
Given IV
Other Names:
  • anti-c-erB-2
  • Herceptin
Other: laboratory biomarker analysis
Correlative studies

Detailed Description:


I. To assess response (confirmed and unconfirmed, complete and partial response) in patients with advanced high-grade salivary gland carcinoma treated with trastuzumab.

II. To assess one-year progression-free survival and one-year overall survival for patients treated with this regimen.

III. To assess the toxicities associated with this treatment regimen in this group of patients.

IV. To measure the indicators of C-erb B2 oncoprotein expression and C-erb B2 oncogene amplification and epidermal growth factor receptor expression and explore the relationship between these markers and response, progression-free survival and overall survival in preliminary fashion.

OUTLINE: Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 8 weeks until disease progression and then every 3 months for 1 year and every 6 months until 3 years from study entry.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed malignant high-grade (poorly differentiated or undifferentiated) salivary gland carcinoma of the head and neck (except adenoid cystic carcinoma) that is either metastatic or recurrent and is not amenable to salvage surgical resection or radiation therapy; eligible histologies are adenocarcinoma, acinic cell carcinoma, mucoepidermoid carcinoma, salivary duct carcinoma and undifferentiated carcinoma
  • Patients must have tumors that car HER-2 gene amplification as determined by (i) fluorescence in situ hybridization (FISH) or (ii) overexpression of HER-2 protein, 2+ to 3+ level assessed by immunohistochemistry
  • Patients must have measurable disease; all measurable disease must be assessed within 28 days prior to registration; all non-measurable disease must be assessed within 42 days prior to registration
  • Patients with known brain metastases are not eligible for this trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
  • Patients must have and must be willing to submit tumor tissue for pathology review and translational medicine studies; patients must be offered the opportunity to participate in specimen banking for future research
  • Patients previously treated with chemotherapy are eligible provided that at least (28 days) has elapsed since the last course of chemotherapy was completed and patient has recovered from all toxicities
  • Prior radiation must have been completed at least 28 days prior to registration and all toxicities must have resolved (in the opinion of the treating investigator); prior surgery must have been completed at least 28 days prior to registration and all surgical adverse events must have resolved (in the opinion of the treating investigator)
  • Patients must not be planning on receiving any other investigational agents, other chemotherapeutic agents, radiation therapy, or hormonal therapy while receiving treatment on this study except for steroids administered for non-disease-related conditions (e.g., insulin for diabetes)
  • Patients must have a Zubrod Performance status of 0-2
  • WBC count >= 2,000 ul within 28 days prior to registration
  • ANC count >= 1,000/ul within 28 days prior to registration
  • Platelet count >= 75,000/ul within 28 days prior to registration
  • Bilirubin =< 2.5 x the institutional upper limit of normal within 28 days prior to registration
  • SGOT or SGPT =< 2.5 x the institutional upper limit of normal within 28 days prior to registration
  • Patients with liver metastases must have bilirubin and SGOT or SGPT =< 5 x the institutional upper limit of normal
  • Serum creatinine < 2.5 x the institutional limit of normal within 28 days prior to registration
  • Patients with a known history of allergic reactions to compounds of similar chemical or biologic composition to trastuzumab are not eligible
  • No prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for five years
  • Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method
  • If day 28 or 42 falls on a weekend or holiday, the limit may be extended to the next working day
  • In calculating days of tests and measurements, the day a test or measurement is done is considered day 0; therefore, if a test is done on a Monday, the Monday four weeks later would be considered day 28; this allows for efficient patient scheduling without exceeding the guidelines
  • Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
  • At the time of patient registration, the treating institution's name and ID number must be provided to the data operations center in Seattle in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered into the data base
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00126607

United States, Texas
Southwest Oncology Group
San Antonio, Texas, United States, 78245
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Madeleine Kane Southwest Oncology Group
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00126607     History of Changes
Other Study ID Numbers: NCI-2012-03172  S0431  U10CA032102  CDR0000437831 
Study First Received: August 2, 2005
Last Updated: February 27, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma, Acinar Cell
Carcinoma, Mucoepidermoid
Salivary Gland Neoplasms
Head and Neck Neoplasms
Mouth Diseases
Mouth Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Salivary Gland Diseases
Stomatognathic Diseases
Antineoplastic Agents processed this record on May 24, 2016